Enhancing Hepatitis B Virus Vaccine Uptake and Immunity Through Long-Acting Antiretroviral Therapy Programmatic Synergy in the US South

We leveraged a long-acting antiretroviral therapy program infrastructure in the US South to vaccinate 32 of 39 (82%) eligible persons with HIV against hepatitis B virus. Novel interprofessional programmatic synergy may facilitate hepatitis B virus vaccine uptake in a population uniquely at risk in the era of 2-drug and injectable antiretroviral therapy.